Introduction {#s1}
============

The control of tuberculosis (TB) has become increasingly more urgent because of the emergence of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB). These two forms of TB are difficult to manage and treat, and known for producing high morbidity and mortality [@pone.0042505-Caminero1], [@pone.0042505-Jain1]. Multidrug-resistant *Mycobacterium tuberculosis* (MDR-Mtb) is resistant to at least both isoniazid (INH) and rifampin (RFP), while extensively drug-resistant *M. tuberculosis* (XDR-Mtb) is resistant to both INH and RFP, in addition to any of the second-line injectable drugs (capreomycin, kanamycin \[KM\] or amikacin) and fluoroquinolone [@pone.0042505-Gandhi1], [@pone.0042505-Masjedi1]. In principle, these resistant *M. tuberculosis* (Mtb) strains are thought to arise through the selection of mutated strains in response to inadequate chemotherapy [@pone.0042505-Caminero1], [@pone.0042505-Jain1], [@pone.0042505-Lomtadze1], [@pone.0042505-Ti1]. It is generally believed that transmission frequency of MDR/XDR-Mtb is lower comparing to drug-susceptible strains, however, exogenous infection with MDR/XDR-Mtb was reported, especially in countries with high human immunodeficiency virus (HIV) infection rates [@pone.0042505-Ti1]--[@pone.0042505-Shah1].

Several studies that genotyped MDR-Mtb isolates have shown that some are genetically related, forming phylogenetic clusters with identical genotypes [@pone.0042505-VazquezGallardo1]--[@pone.0042505-Devaux1]. Most of these reports showed that MDR-Mtb genetic clusters consist of isolates that belong to the Beijing genotype [@pone.0042505-Kubica1], [@pone.0042505-Sun1], [@pone.0042505-Devaux1], suggesting a high tendency to become MDR-Mtb Beijing strains. Beijing strains are endemically predominant in East Asia [@pone.0042505-vanSoolingen1] and are epidemically spreading in isolated regions such as Cuba, Eastern Europe, sub-Saharan Africa, and Vietnam [@pone.0042505-EuropeanConcertedActiononNewGenerationGenetic1]. Overall, Beijing strains of Mtb represent approximately 10% of MDR-Mtb isolates worldwide [@pone.0042505-EuropeanConcertedActiononNewGenerationGenetic1].

In 2009, Japan had intermediate TB incidence (19.0/100,000) [@pone.0042505-Ministry1] and a low HIV infection rate (new HIV infections, 0.8/100,000) (calculated from data in [@pone.0042505-Ministry2]). The prevalence of new MDR-TB cases in Japan was 0.7% and new XDR-TB cases was 0.2% [@pone.0042505-Tuberculosis1]. Using this statistical ratio, it is estimated that approximately 170 new MDR-TB cases including approximately 50 XDR-TB cases occur every year. Moreover, greater than 70% of all Mtb isolated in Japan were of the Beijing genotype [@pone.0042505-Murase1].

Osaka Prefecture has historically had the highest endemic rate of TB in Japan since 1991. The rate of TB incidence in Osaka in 2009 was determined to be 31.5/100,000 (16), while maintaining a low HIV infection rate (1.9/100,000) (calculated from data in [@pone.0042505-Ministry2]). Osaka Prefecture is located in central Japan and has an area of 1,989 km^2^. It is a highly industrialized area including Osaka, the third most populous city in Japan, and over 8 million people have lived in Osaka Prefecture since 1973. In Osaka, both MDR-TB and XDR-TB cases have been reported, but little is known about the transmission of MDR/XDR-Mtb and the prevalence of Beijing lineage genotypes among MDR-Mtb isolates.

In the present study, we characterized a total of 1,110 Mtb isolates obtained from TB patients in Osaka prefecture and a neighboring area utilizing mycobacterial interspersed repetitive units-various number of tandem repeats (MIRU-VNTR) typing to investigate transmission of MDR-TB. Our data revealed that MDR/XDR-Mtb clones displayed genotypes that are not typically seen in drug-susceptible isolates and these strains are colonizing and spreading in Osaka Prefecture and its neighboring area.

Materials and Methods {#s2}
=====================

Mtb Isolates {#s2a}
------------

We analyzed 89 MDR-Mtb and 1021 non MDR-Mtb isolates collected in Osaka Prefectural Institute of public health. Eighty-nine MDR-Mtb isolates, which were delivered from three hospitals having tuberculosis ward in Osaka prefecture, were isolated from MDR-TB patients in Osaka Prefecture (except Osaka city and southeast area of Osaka prefecture) and neighboring local governments from April 2000 to March 2009. Of 1021 non MDR-Mtb isolates of which genetic diversity and/or genotypes were compared with those of MDR-Mtb, 471 isolates were sent to the institute for routine examinations (identifications of *Mtb*, drug susceptibility, and/or determination of the source of TB outbreaks) by Osaka prefectural health care centers from April 2000 to March 2007 and by neighboring local governments from April 2000 to March 2009. The remaining 550 were isolates from newly diagnosed TB patients in Osaka prefecture (except Osaka city and southeast area of Osaka prefecture) and sent to the institute for population-based molecular epidemiology of TB (population-based non MDR-Mtb). All Mtb isolates were confirmed whether they were MDR-Mtb or not in the laboratories of the hospitals, commercial laboratories, or Osaka Prefectural institute of public health. Although we could not fully obtain patient data including age, sex, residence area, year of case reported, and history of TB, duplication of patients of the isolates were avoided by the unified patients' identification numbers and the names of the patients.

Drug Susceptibility Test {#s2b}
------------------------

To determine the ratio of XDR-Mtb for MDR-Mtb, we performed drug susceptibility tests of MDR-Mtb. When MDR-Mtb isolates were grown on Ogawa medium, 15 of the 89 isolates provided failed to grow on this medium because they perished. Therefore, for the remaining 74, minimum inhibitory concentrations (MICs) for INH, RFP, KM, streptomycin (SM), ethambutol (EB), and the fluoroquinolones, levofloxacin (LVFX), spafloxacin (SPFX), and ciprofloxacin (CPFX) were determined using the micro-dilution test BrothMIC MTB I (Kyokuto, Tokyo). Mtb isolates resistant to INH, RFP, KM and at least one fluoroquinolone were defined as XDR-Mtb.

DNA Extraction and Genotyping {#s2c}
-----------------------------

Chromosomal DNA was extracted by combining chloroform extraction and mechanical disruption [@pone.0042505-Kozak1] from cultures grown on Ogawa medium or MGIT liquid medium for all 89 isolates. DNA was extracted from all 1110 isolates and genotyped using the MIRU-VNTR type testing [@pone.0042505-Murase1], [@pone.0042505-Supply1] for 26 loci to identify transmission routes. Single-locus variants involving QUB4120, QUB11a, QUB11b, and QUB26 were regarded as identical in this study. All 89 MDR-Mtb isolates and 550 population-based non MDR-Mtb were examined by PCR to determine the frequency of the Beijing lineage [@pone.0042505-Warren1]. Isolates determined as genetically related to the Beijing lineage were further classified into ancient and modern sub-lineages by PCR [@pone.0042505-Wada1], [@pone.0042505-Plikaytis1].

Sequence Analysis {#s2d}
-----------------

MDR-Mtb isolates showing identical genetic patterns were analyzed by their SNPs for *katG*, *inhA*, *rpoB*, *rrs*, and *gyrA*. PCR products were amplified using the following primers: *katG*-Fw, CGCAGCGAGAGGTCAGTGGCCAG; *katG*-Rv, ATGGCCATGAACGACGTCGAAAC; *inhA-*Fw, TCACACCGACAAACGTCACGAGC; *inhA*-Rv, AGCCAGCCGCTGTGCGATCGCCA; *rpoB*-Fw, CAGGACGTGGAGGCGATCAC; *rpoB*-Rv, GAGCCGATCAGACCGATGTTGG; *rrs*-Fw, TCACCATCGACGAAGCTCCG; *rrs*-Rv, CTAGACGCGTCCTGTGCATG; *gyrA*-Fw, AGCGCAGCTACATCGACTATGCG; and *gyrA*-Rv, CTTCGGTGTACCTCATCGCCGCC. All amplified products were purified and sequenced using the Big Dye Terminator Cycle Sequencing Kit (Applied Biosystems Inc., Japan) on a ABI Prism 3100 Genetic Analyzer (Applied Biosystems Inc.).

Results {#s3}
=======

Identification of MDR/XDR-Mtb and Drug Sensitivity Patterns {#s3a}
-----------------------------------------------------------

The drug susceptibility patterns of 74 MDR-Mtb isolates were identified to investigate the prevalence of XDR-Mtb among MDR-Mtb isolates ([Table 1](#pone-0042505-t001){ref-type="table"}) and 36 (48.6%) were determined to be XDR-Mtb. Of these 36 XDR-Mtb, 25 (33.8%) were determined to be resistant to all eight drugs tested in this study. Of the 38 MDR-Mtb isolates, eight were resistant only to INH and RFP (10.8%), while the remaining 30 were resistant to INH, RFP, and either one or more second-line injectable drugs or one or more fluoroquinolone.

10.1371/journal.pone.0042505.t001

###### Drug resistance patterns of 74 MDR-TB isolates.

![](pone.0042505.t001){#pone-0042505-t001-1}

  MDR or XDR    Total number of isolates (%)[\*](#nt101){ref-type="table-fn"}   Drug resistance pattern   Number of isolates (%)[\*](#nt101){ref-type="table-fn"}                                      
  ------------ --------------------------------------------------------------- ------------------------- --------------------------------------------------------- ---- ---- ---- ------ ------ ------ -----------
  XDR                                     36 (48.6)                                       INH                                       RFP                             KM   SM   EB   LVFX   CPFX   SPFX   25 (33.8)
                                                                                          INH                                       RFP                             KM        EB   LVFX   CPFX   SPFX   8 (10.8)
                                                                                          INH                                       RFP                             KM             LVFX   CPFX   SPFX    1 (1.4)
                                                                                          INH                                       RFP                             KM             LVFX   CPFX           1 (1.4)
                                                                                          INH                                       RFP                             KM   SM        LVFX   CPFX   SPFX    1 (1.4)
  MDR                                     38 (51.4)                                       INH                                       RFP                                  SM   EB   LVFX   CPFX   SPFX    4 (5.4)
                                                                                          INH                                       RFP                                       EB   LVFX   CPFX   SPFX    4 (5.4)
                                                                                          INH                                       RFP                                  SM        LVFX   CPFX   SPFX    1 (1.4)
                                                                                          INH                                       RFP                                  SM               CPFX   SPFX    1 (1.4)
                                                                                          INH                                       RFP                                  SM   EB          CPFX           1 (1.4)
                                                                                          INH                                       RFP                             KM   SM   EB                         6 (8.2)
                                                                                          INH                                       RFP                                  SM   EB                         3 (4.1)
                                                                                          INH                                       RFP                                       EB                         5 (6.8)
                                                                                          INH                                       RFP                                  SM                              4 (5.4)
                                                                                          INH                                       RFP                             KM                                   1 (1.4)
                                                                                          INH                                       RFP                                                                 8 (10.8)

Percentage of MDR-TB isolates determined drug sensitivity.

Comparison of the Genetic Diversity of MDR-Mtb and Non MDR-Mtb {#s3b}
--------------------------------------------------------------

To bring out the genetic aspects of MDR-Mtb, we compared the cluster formation resulting from MIRU-VNTR genotyping and the frequency of Beijing lineage with those of population-based non MDR-Mtb (Table2). Among 89 MDR-Mtb isolates, 24 (27.0%) isolates were classified into six identical clusters. In population-based non MDR-Mtb, sixty-five identical clusters were formed from 216 (39.3%) isolates. The ratio of cluster-forming isolates in MDR-Mtb was significantly lower than it in population-based non MDR-Mtb.

10.1371/journal.pone.0042505.t002

###### Comparison of the genetical diversity of MDR-Mtb and non MDR-Mtb.

![](pone.0042505.t002){#pone-0042505-t002-2}

                 The number of clusters          The number of isolates                                                
  ------------- ------------------------ -------------------------------------- -------------------------------------- ------------------------------------------
  MDR-Mtb                  6                               24                                     79                                       60
                                                         27.0%                                  88.8%                   75.9%[\*\*](#nt103){ref-type="table-fn"}
  non MDR-Mtb              65             216[\*](#nt102){ref-type="table-fn"}   425[\*](#nt102){ref-type="table-fn"}                     328
                                                         39.3%                                  77.3%                   77.2%[\*\*](#nt103){ref-type="table-fn"}

significant difference (P\<0.05, Fisher's exact test).

percentage for Beijing isolates.

The frequency of the Beijing Lineage was 88.8% in MDR-Mtb and 77.3% in population-based non MDR-Mtb, showing significantly higher frequency of the Beijing Lineage in MDR-Mtb isolates. The Beijing lineage can be divided into ancient and modern sub-lineage by the insertion of IS*6110* into the NTF region of the genome [@pone.0042505-Wada1]. About the ratio of ancient sub-lineage and modern, the significant difference was not seen in MDR-Mtb isolates and population-based non MDR-Mtb (75.9% and 77.2%, respectively).

Comparison of MIRU-VNTR Patterns between MDR- andnon-MDR-Mtb Isolates {#s3c}
---------------------------------------------------------------------

The MIRU-VNTR patterns of the 6 identical clusters constructed from MDR-Mtb isolates OM-V02, OM-V03, OM-V04, OM-V06, OM-V12, and OM-V32 were shown in [Table 3](#pone-0042505-t003){ref-type="table"}. To verify these MIRU-VNTR pattern were specific to MDR-Mtb isolates or not, we genotyped not only population-based non MDR-Mtb isolates but also other 471 non MDR-Mtb isolates (total 1021 non MDR-Mtb isolates were genotyped) and all MDR-Mtb clusters and non-MDR-Mtb clusters with incidence rates of more than 1.0% per total isolates are presented in [Table 3](#pone-0042505-t003){ref-type="table"}. Importantly four clusters, OM-V02, OM-V03, OM-V04, and OM-V06, consisted of only MDR-Mtb isolates and none of the 1,021 non-MDR-Mtb isolates. These four clusters together were designated as a MDR-Mtb-specific cluster (MDR-Mtb SC). In particular, the incidence rate of OM-V02 (1.1% of 1,110 isolates) was the highest among the MDR-Mtb SC and equal to that of OM-V801, the sixth largest non-MDR-Mtb cluster.

10.1371/journal.pone.0042505.t003

###### MIRU-VNTR profiles of phylogenetic clusters.
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  Cluster type[\*](#nt104){ref-type="table-fn"}    Cluster No.   Number of alleles in the MIRU-VNTR loci[†](#nt105){ref-type="table-fn"}   number of isolates in cluster   Beijing sublineage                                                                                                                     
  ----------------------------------------------- ------------- ------------------------------------------------------------------------- ------------------------------- -------------------- --- --- --- --- --- --- --- --- ---- --- --- --- --- --- --- --- --- ---- --- ---- --- ---- ---- ---- ---- ------- -------------
  MDR-TB                                             OM-V02                                         2                                                    1                         3            8   7   3   5   2   4   4   4   3    4   3   4   3   5   2   4   4   7    4   9    7   8    10   11   0    (1.1)     ancient
                                                     OM-V03                                         2                                                    3                         3            5   7   3   5   3   3   4   4   3a   2   3   4   2   4   3   3   2   10   4   25   6   8    4    4    0    (0.4)     ancient
                                                     OM-V04                                         3                                                    3                         3            5   7   3   5   3   3   2   4   3    4   3   2   3   4   3   3   4   5    4   8    1   7    9    3    0    (0.3)     ancient
                                                     OM-V06                                         2                                                    3                         3            5   7   3   5   3   3   3   4   3    4   4   3   3   3   3   3   4   7    4   5    5   8    10   2    0    (0.2)     modern
  Mix C                                              OM-V12                                         2                                                    3                         4            5   7   2   5   3   3   4   4   3    3   3   4   3   5   4   3   5   7    2   8    8   2    11   2    7    (0.8)     ancient
                                                     OM-V32                                         2                                                    3                         3            5   7   3   5   3   3   4   4   3    4   4   4   3   3   3   3   4   7    4   8    8   8    9    2    11   (1.2)     modern
                                                     OM-V29                                         2                                                    3                         3            5   7   3   5   3   3   4   4   3    4   4   4   3   3   3   3   4   7    4   5    5   8    8    1    30   (2.8)     modern
                                                     OM-V05                                         2                                                    3                         3            5   7   3   5   3   3   4   4   3a   3   3   4   3   4   3   3   2   10   4   5    5   6    8    1    16   (1.5)     ancient
                                                     OM-V031                                        2                                                    3                         4            5   7   3   5   3   3   4   4   3    3   3   4   3   5   4   3   5   7    2   8    7   2    9    1    6    (0.6)     ancient
                                                     OM-V091                                        2                                                    3                         3            5   7   3   5   3   3   4   4   3    4   3   4   3   5   2   3   4   7    4   5    7   10   8    1    4    (0.5)     ancient
                                                     OM-V021                                        2                                                    3                         3            5   4   3   5   3   3   4   4   3    4   4   4   3   3   3   3   4   7    4   8    6   8    10   1    4    (0.5)     modern
                                                     OM-V070                                        1                                                    5                         1            5   1   3   3   2   2   3   4   3a   2   2   4   3   4   1   3   2   12   2   7    2   9    3    1    3    (0.4)   non Beijing
                                                     OM-V067                                        2                                                    3                         3            5   7   1   5   3   1   4   4   3    4   3   4   3   3   3   3   4   7    4   8    9   8    10   1    3    (0.4)     modern
                                                     OM-V08                                         2                                                    3                         3            5   7   3   4   3   3   4   4   3    4   0   2   3   4   3   3   4   1    6   8    3   8    10   1    2    (0.3)     ancient
                                                     OM-V068                                        2                                                    3                         3            6   5   3   3   1   1   3   3   3    2   1   2   6   3   3   2   4   12   2   2    2   3    2    1    1    (0.2)   non Beijing
                                                     OM-V087                                        2                                                    1                         3            5   7   3   5   3   3   4   4   3    4   3   4   3   5   2   4   4   7    4   7    6   8    11   1    1    (0.2)     ancient
  non MDR                                            OM-V127                                        2                                                    3                         4            5   7   3   5   3   3   4   4   3    3   3   4   3   5   4   3   5   7    2   8    7   2    11   0    13   (1.2)     ancient
                                                     OM-V228                                        2                                                    3                         3            5   7   3   5   3   3   4   4   3a   4   3   4   3   5   3   3   4   7    4   8    7   8    5    0    13   (1.2)     ancient
                                                     OM-V801                                        2                                                    3                         3            5   5   3   3   2   1   2   4   3a   2   1   2   3   3   2   2   4   8    4   2    2   4    2    0    11   (1.1)     ancient

MDR: clusters consisted of only MDR-TB isolates, Mix C: clusters consisted of MDR-TB isolates and non MDR-TB isolates, non MDR: clusters consisted of only non-MDR-TB isolates for which the ratio of total non MDR-TB isolates is \>1%.

The order of MIRU-VNTR loci is as follows: 0580, 0960, 1644, 2531, 2996, 3007, 3192, 4348, 0802, 2165, 0577, 3239 (3a contains irregular-size alleles), 0424, 1955, 2401, 3690, 4156, 2074, 2372, 3155, 3336, 1895, 2163a, 2163b, 4052, 4120.

Percentage of all TB isolates.

In contrast, two of the six MDR-Mtb clusters, OM-V12 and OM-V32, had the MIRU-VNTR patterns that were also found in non-MDR-Mtb isolates. The other 65 MDR-Mtb isolates formed 10 clusters (OM-V29, OM-V05, OM-V031, OM-V091, OM-V021, OM-V070, OM-V067, OM-V08, OM-V068, and OM-V087) with one or multiple non-MDR-Mtb isolates. The clusters were designated as a mixed cluster (Mix C) type, of which MIRU-VNTR pattern were observed in both MDR and non-MDR Mtb. The remaining 55 MDR-Mtb showed unique MIRU-VNTR patterns.

Different incidence ratios of MDR/non-MDR-Mtb were observed among clusters. For example, OM-V29, which was the largest cluster, consisted of only one MDR-Mtb and 30 non-MDR-Mtb isolates, while two of nine isolates were MDR-Mtb in OM-V12 (the eighth largest cluster) and two of 13 were MDR-Mtb in OM-V32 (the third largest cluster).

MIC Values and Mutation Patterns of MDR-Mtb SC {#s3d}
----------------------------------------------

To further investigate whether isolates in each cluster in MDR-Mtb SC (OM-V02, OM-V03, OM-V04, and OM-V06) were identical clones, MICs and mutations in the resistance-associated genes were analyzed ([Table 4](#pone-0042505-t004){ref-type="table"}). Although nine of these isolates (Nos. 010, 019, 030, 063, 073, 082, 095, and 004) belonging to OM-V02 were XDR-Mtb and the remaining two (051, 052) were MDR-Mtb, the MICs of these isolates revealed slight variations and all isolates possessed D516V in *rpoB*, S315T in *katG*, and a nucleotide substitution in *rrs* (adenine to guanine at position 1400 in the gene). Nos. 19 and 95 had additional mutations in *katG* and *rpoB*, respectively. Regarding isolates belonging to the OM-V03 cluster, of which MICs and mutations were similar for all isolates, only isolate No. 029 showed a higher MIC value to INH and an additional mutation in *inhA*. Isolate Nos. 002 and 020 in cluster OM-V04 shared the same MIC and mutation patterns. Taken together, these data suggest that OM-V02, OM-V03, and OM-V04 are three clonal strains.

10.1371/journal.pone.0042505.t004

###### MIC values for drugs and mutations in *rpoB*, *katG*, *inhA, gryA,* and *rrs* of isolates in the MDR-TB SC.

![](pone.0042505.t004){#pone-0042505-t004-4}

  cluster              MDR isolates No.             MDR or MDR   MIC (ug/ml)   mutations                                                                                                                    
  --------- -------------------------------------- ------------ ------------- ----------- ------- ------- ---- ------ ------- ------ -------------------------- ---------------------- --------- ---------- ----------------------------
  OM-V02                     005                       XDR            8           16        32     \>128   64    4      32      4           Asp 516 Val              Ser 315 Thr         none     A 1400 G           Asp 94 Ala
                             010                       XDR            8           16        64     \>128   64    2       1      4           Asp 516 Val              Ser 315 Thr         none     A 1400 G           Asp 94 Ala
                             019                       XDR            8           32        32     \>128   64    2       1      4           Asp 516 Val          Ser 315 Thr, G 944 C    none     A 1400 G   Asp 94 Ala, Thr 95 Thr/Pro
                             030                       XDR            8            8        16     \>128   16    2       1      2           Asp 516 Val              Ser 315 Thr         none     A 1400 G           Asp 94 Ala
                             050                       MDR            8          \>32       32     \>128   64   0.5    0.125   0.25         Asp 516 Val              Ser 315 Thr         none     A 1400 G              none
                             051                       MDR            8           32        64     \>128   64   0.5    0.125   0.5          Asp 516 Val              Ser 315 Thr         none     A 1400 G              none
                             063                       XDR            8           16        32     \>128   32    2       1      4           Asp 516 Val              Ser 315 Thr         none     A 1400 G           Asp 94 Ala
                             073                       XDR           16            8        16     \>128   16    4      16      4           Asp 516 Val              Ser 315 Thr         none     A 1400 G           Asp 94 Ala
                             082                       XDR            8           16        64     \>128   64    2       1      2           Asp 516 Val              Ser 315 Thr         none     A 1400 G           Asp 94 Ala
                             095                       XDR           32           16       \>128     8     4     2       1      2     Asp 516 Val, Leu 533 Pro       Ser 315 Thr         none     A 1400 G           Asp 94 Ala
                             004                       XDR            8            4        16     \>128   16    2       1      4           Asp 516 Val              Ser 315 Thr         none     A 1400 G           Asp 94 Ala
  OM-V03                     013                       XDR            8          \>32       64     \>128   16    8       4      8           Ser 531 Leu              Ser 315 Thr         none     A 1400 G           Asp 94 Gly
                             029                       XDR          \>32         \>32       64     \>128   16    8       4      8           Ser 531 Leu              Ser 315 Thr        C -15 T   A 1400 G         Asp 94 Gly/Asp
             061[\*](#nt107){ref-type="table-fn"}                                                                                           Ser 531 Leu              Ser 315 Thr         none                        Asp 94 Gly
                             064                       XDR            8          \>32       128    \>128   16    8       4      16          Ser 531 Leu              Ser 315 Thr         none     A 1400 G           Asp 94 Gly
  OM-V04                     002                       MDR            4           32         4       2     8     2       1      2           Ser 531 Leu                  none           C -15 T     none     Asp 94 Ala, Thr 95 Thr/Pro
                             020                       MDR            4          \>32        4       2     4     2       1      2           Ser 531 Leu                  none           C -15 T     none             Asp 94 Ala
                             049                       MDR           32          \>32      \>128   \>128   16   0.25   0.125   0.25         His 526 Arg                  none           C -15 T   A 1400 G              none
  OM-V06                     044                       XDR            4            1       \>128    64     64    16      8      32          His 526 Ser                  none            none       none             Asp 94 Gly
                             042                       XDR           64            8       \>128    16     32    8       4      8           Ser 531 Leu                  none            none       none                none

MIC could not be determined because the isolate perished before we received.

We described characteristics of the cases with OM-V02, OM-V03, and OM-V04 in [Table 5](#pone-0042505-t005){ref-type="table"}. About OM-V02, the age distribution of patients was wide and seven patients were younger than 60 years old. The earliest patients (Nos 019 and 073) were reported in 2002 and the last one (No. 063) was reported in 2008. In 11 patients, seven patients (005, 019, 050, 051, 082, 095, and 004) were newly diagnosed as MDR-TB. As to OM-V03, the age distribution of patients was the age of between 30 and 89, the period when patients reported was from 2000 to 2008, and two of four patients were newly diagnosed. Both patients with OM-V04 were newly diagnosed, one was reported in her 30′s in 2002 and the other was reported in her 60′s in 2003.

Discussion {#s4}
==========

To understand the transmission dynamics of MDR/XDR-Mtb in Osaka Prefecture and its neighboring region, an area with the highest TB endemicity in Japan, molecular epidemiological analyses of 89 MDR/XDR-Mtb was performed. Overall, our study demonstrated the following features of Mtb found in Osaka Prefecture and its neighboring regions: 1) a high XDR-Mtb to MDR-Mtb ratio (48.5%); 2) a high ratio (88.8%) of Beijing lineage genotypes among MDR-Mtb; 3) the spread of MDR/XDR-Mtb isolates that share distinct MIRU-VNTR patterns.

Our data revealed a high XDR-Mtb to MDR-Mtb ratio (48.5%) in the studied area. The XDR/MDR ratio in Japan, 31.5% [@pone.0042505-Tuberculosis1] is higher than that of other countries [@pone.0042505-Jain1], [@pone.0042505-Shah2]. One of the causes for this high ratio seems to be the presence of the MDR-Mtb SC. Two of the MDR-Mtb SC consisted of only XDR-Mtb isolates and one contained nine XDR-Mtb ([Table 4](#pone-0042505-t004){ref-type="table"}). By excluding XDR-Mtb isolates from the MDR-Mtb SC, the XDR/MDR ratio in this study was determined to be 40.0%, which is still significantly higher than the national ratio. From the available information, we cannot specify what factors result in the increase in XDR/MDR ratio in Osaka. In Osaka Prefecture and Japan, the prevalence of TB patients co-infected with HIV is low, indicating that HIV is not a considerable factor involved in this high XDR/MDR ratio.

10.1371/journal.pone.0042505.t005

###### Characteristics of cases and mutations of isolates in the MDR-TB SC.

![](pone.0042505.t005){#pone-0042505-t005-5}

  Cluster    MDR isolate No.   MDR/XDR[\*](#nt108){ref-type="table-fn"}    Sex     Age(years)   Year of case reported   History of TB   additional mutation
  --------- ----------------- ------------------------------------------ -------- ------------ ----------------------- --------------- ---------------------
  OM-V02           005                           XDR                      Female     50--59             2004                 New       
                   010                           XDR                       Male      50--59             2006              relapsed     
                   019                           XDR                       Male      40--49             2002                 New            *katG,gyrA*
                   030                           XDR                      Female     50--59             2007              relapsed     
                   050                           MDR                       Male      20--29             2003                 New       
                   051                           MDR                      Female     50--59             2003                 New       
                   063                           XDR                       Male      70--79             2008               Unknown     
                   073                           XDR                       Male      70--79             2002               Unknown     
                   082                           XDR                      Female     20--29             2003                 New       
                   095                           XDR                       Male      80--89             2005                 New              *rpoB*
                   004                           XDR                       Male      90--99             2004                 New       
  OM-V03           013                           XDR                       Male      80--89             2000               Unknown     
                   029                           XDR                      Female     30--39             2006                 New           *inhA, gyrA*
                   061                                                     Male     Unknown             2008               Unknown     
                   064                           XDR                       Male      60--69             2007                 New       
  OM-V04           002                           MDR                       Male      60--69             2003                 New              *gyrA*
                   020                           MDR                       Male      30--39             2002                 New       

MDR, multidrug resistant, XDR, extensively-drug resistant.

In this study, the percentage of Beijing lineage genotypes found among MDR-Mtb isolates (79/89, 88.8%) was significantly higher than that of population-based non MDR-Mtb (425/550, 77.3%) which was almost same as obtained nationwide in Japan [@pone.0042505-Murase1]. The Beijing lineage is of particular concern because it has a high predilection for developing drug resistance [@pone.0042505-Shah2], which may explain the high percentage of the Beijing lineage in MDR-Mtb seen in this study. Beijing strains can be classified into modern and ancient sub-lineages. Although the modern Beijing sub-lineage was reported to be disseminating worldwide [@pone.0042505-Hanekom1], the ratio of modern sub-lineage of the 79 MDR-Mtb isolates belonging to Beijing lineage was 24.1%, which is similar to that reported for Japan [@pone.0042505-Wada2], [@pone.0042505-Iwamoto1]. These data suggest that there is no discrepancy of frequency of acquiring MDR/XDR phenotypes between ancient and modern sub-lineages.

Although the ratio of cluster-forming isolates in MDR-Mtb was significantly lower than that in population-based non MDR-Mtb (27.0% and 39.3%, respectively), 6 identical clusters were found in MDR-Mtb isolates. It was been reported that some MDR-Mtb isolates form clusters with identical genotypes [@pone.0042505-VazquezGallardo1]--[@pone.0042505-Devaux1], [@pone.0042505-Murase2]. Although our collection of Mtb isolates analyzed in this study did not fully cover all Mtb isolates before 2007, it is notable that four clusters consisting of 20 (22.4%) MDR-Mtb isolates showed unique MIRU-VNTR patterns that were not detected in non-MDR/XDR-Mtb isolates from Osaka Prefecture and neighboring regions. Based on similarities of genotype, drug resistance, and mutations, we regarded all isolates belonging to OM-V02 and OM-V03, and two isolates from OM-V04 (Nos. 002 and 020; [Table 4](#pone-0042505-t004){ref-type="table"}) as clones. Of these 17 isolates, 11 isolates were isolated from newly diagnosed MDR-TB patients. It was shown that at least these 11 cases were caused by infection not by result of inadequate chemotherapy. Seven of 11 cases with OM-V02 Mtb were newly diagnosed, i.e., OM-V02 Mtb isolates likely transmitted. Since insufficient epidemiological information was available, we could not predict whether the cause of the transmission of these infectious MDR-Mtb were due to social behavior of patients. Chronologically, for each OM-V02 clone, although the additional mutation was observed in No.019, it was isolated earlier than other XDR-Mtb isolates. XDR-Mtb isolates 019 and 073 were isolated before the Nos. 050 and 051 from MDR-Mtb cases. These data suggest that some MDR-V02 clones have remained multidrug resistant and some other derivatives had acquired further drug resistance and had become XDR-Mtb during the spread through multiple infectious routes.

In addition, two additional OM-V02 clones were isolated after the study period. Of these, one was isolated from a new MDR-TB case and the other was from a re-infected patient cured of a drug-sensitive Mtb infection (different from OM-V02) two years prior to reinfection. Although the infectious routes of these two additional cases were not specified, these cases support the evidence of expansion by transmission of OM-V02 Mtb. OM-V02 clones may be warned as a big problem in public health, because XDR-Mtb belonging to OM-V02 was highly resistant Mtb ([Table 4](#pone-0042505-t004){ref-type="table"}) and caused XDR-TB in the wide range of ages (Table5). The systematical and rapid test of 2^nd^ line drugs sensitivity and genotyping are needed to detect OM-V02 clones or such drug resistant strains. Furthermore, the improvement of TB control containing enforced management of patients and thorough contact investigation will be needed to prevent expansion of OM-V02 clones or such strains.

Of 89 MDR-Mtb isolates, the most frequent mutation conferring RFP resistance was S531L in *rpoB* (38/89, 42.7%; data not shown), and the D516V mutation in *rpoB* of OM-V02 Mtb was the third most frequent mutation conferring RFP resistance in 89 MDR-Mtb. The S531L mutation in *rpoB* was reported to not cause reduction of fitness, especially in the Beijing lineage [@pone.0042505-Billington1], [@pone.0042505-Mariam1], and the D516V mutation did not to impair fitness compared with drug-sensitive clinical isolates [@pone.0042505-OSullivan1]. Thus, it is conceivable that the combination with the phylogenetic structures of OM-V02 MDR-Mtb and the mutations conferring resistance to OM-V02 carries a relatively low fitness deficit. Although we could not determine the veritable cause of OM-V02 predominance in this study, it is possible that some Mtb clones like OM-V02 retain or strengthen infectiousness and/or have the ability to progress to an active form of the disease following the acquisition of drug resistance.

In spite of the high ratio of OM-V02 among MDR/XDR Mtb isolates, we did not detect non-MDR/XDR-Mtb strains with genotypes the same as OM-V02. Thus, it is likely that a drug-sensitive ancestral clone of OM-V02 or its derivatives have lower fitness cost than OM-V02 MDR/XDR-Mtb strains. This suggests that the well-organized medical treatment of TB patients with multiple drugs in Osaka, Japan might bring about colonization by selected transmissible highly drug-resistant Mtb clones. Thus, this study highlights that the spread of highly drug-resistant Mtb is not only a problem in developing [@pone.0042505-Shah2] countries, but also in developed countries with excellent medical care systems, such as Japan.
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